A Safety, Tolerability and Efficacy Study of VRDN 001 in Healthy Volunteers and Persons With Thyroid Eye Disease (TED)

  • End date
    Dec 20, 2023
  • participants needed
  • sponsor
    Viridian Therapeutics, Inc.
Updated on 4 October 2022
Accepts healthy volunteers


The investigational drug, VRDN-001, is a monoclonal antibody that inhibits the activity of a cell surface receptor called insulin-like growth factor-1 receptor (IGF-1R). Inhibition of IGF-1R may help to reduce the inflammation and associated tissue swelling that occurs in patients with thyroid eye disease (TED). This clinical trial will evaluate the safety, tolerability and pharmacokinetics (the concentration of drug in the blood over time) of VRDN-001 in healthy volunteers and in patients with TED. Study participants with TED will also be evaluated over time for changes in their signs and symptoms of TED compared to their baseline measurements.

Condition Thyroid Eye Disease
Treatment Placebo, VRDN-001
Clinical Study IdentifierNCT05176639
SponsorViridian Therapeutics, Inc.
Last Modified on4 October 2022


Yes No Not Sure

Inclusion Criteria

Must have moderate to severe active TED with documented evidence of ocular symptoms or
signs that began within 1 year prior to screening
Must have Clinical Activity Score (CAS) of ≥ 4 on the 7-item scale for the study (more
proptotic) eye
Must agree to use highly effective contraception as specified in the protocol
Female TED participants must have a negative serum pregnancy test

Exclusion Criteria

Must not have received prior treatment with another anti-IGF-1R monoclonal antibody
Must not have used oral corticosteroids within 4 weeks prior to Day 1
Must not have received rituximab, tocilizumab or other immunosuppressive agents within
days prior to Day 1
Must not have evidence of optic nerve involvement within the previous 6 months
Must not have corneal decompensation in the study eye unresponsive to medical
Must not have had previous orbital irradiation or surgery for TED in the study eye
Must not have a history inflammatory bowel disease, or clinically significant ear
pathology or hearing impairment
Must not have received an investigational agent for any condition within 60 days
Female TED participants must not be pregnant or lactating
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note